NeuroSense Therapeutics Ltd.
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$11.1M
- Total assets
- $1.0M
- Market cap
- $27.1M
Source: SEC EDGAR · updated Jun 8, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $27.1M
- Shares outstanding
- 37.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 9, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $11.1M.
- Trading 71% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NeuroSense Therapeutics Ltd..
Write a review
News about NeuroSense Therapeutics Ltd.
News & sentiment via Polygon.io
